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ARTICLE
Pharmacometabolomics Informs About Pharmacokinetic
Profile of Methylphenidate
Rima Kaddurah-Daouk1,2, Thomas Hankemeier3,4, Elizabeth H. Scholl11, Rebecca Baillie6, Amy Harms3,4, Claus Stage7,
Kim P. Dalhoff7, Gesche J}urgens8, Olivier Taboureau9, Grace S. Nzabonimpa10, Alison A. Motsinger-Reif5,11,
Ragnar Thomsen12, Kristian Linnet12, Henrik B. Rasmussen13,14, INDICES Consortium† and
Pharmacometabolomics Research Network
Carboxylesterase 1 (CES1) metabolizes methylphenidate and other drugs. CES1 gene variation only partially explains
pharmacokinetic (PK) variability. Biomarkers predicting the PKs of drugs metabolized by CES1 are needed. We identified
lipids in plasma from 44 healthy subjects that correlated with CES1 activity as determined by PK parameters of
methylphenidate including a ceramide (q value5 0.001) and a phosphatidylcholine (q value5 0.005). Carriers of the CES1
143E allele had decreased methylphenidate metabolism and altered concentration of this phosphatidylcholine
(q value5 0.040) and several high polyunsaturated fatty acid lipids (PUFAs). The half-maximal inhibitory concentration (IC50)
values of chenodeoxycholate and taurocholate were 13.55 and 19.51 lM, respectively, consistent with a physiological
significance. In silico analysis suggested that bile acid inhibition of CES1 involved both binding to the active and superficial
sites of the enzyme. We initiated identification of metabolites predicting PKs of drugs metabolized by CES1 and suggest lipids
to regulate or be regulated by this enzyme.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, ; doi:10.1002/psp4.12309
Study Highlights
WHAT IS THECURRENTKNOWLEDGEONTHETOPIC?
 The activity of CES1, the enzyme responsible for
degrading MPH, is highly variable. The underlying con-
tributors to that variability are unclear.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study shows that the PKs of MPH may be used
to identify metabolic pathways, which regulate CES1
activity or are regulated by CES1.
WHATDOESTHIS STUDYADDTOOURKNOWLEDGE?
 The present study identified CES1 as a potential
regulator of the concentration of EPA, an anti-
inflammatory fatty acid, in lipids. It also identified bile
acids that were correlated with the PK of MPH and
subsequently shown to inhibit CES1 activity in vitro.
Finally, the study has linked MPH PK and plasma
lipid concentrations to CES1 genotype and apparent
enzyme activity.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 Metabolomics is a tool, which may be able to identify
metabolic pathways contributing to variability in drug
concentration.
Methylphenidate (MPH) is a central nervous system stimu-
lant used in the treatment of attention deficit hyperactivity
disorder.1 Its medical use began in 1960; the drug became
increasingly prescribed by the late 1980s and early 1990s
when the diagnosis of attention deficit hyperactivity disorder
itself became more widely accepted and prevalent.2 Up to
30% of patients treated with MPH either do not achieve the
desired improvement in symptom severity or are intolerant
to the treatment.3
The individual variation in the response to MPH is poorly
understood but factors affecting the activity of CES1 may
be important in determining individual variation in plasma
concentration and clinical outcome of the drug.4
The pharmacokinetic (PK) properties of a drug are deter-
mined by the processes of its absorption, distribution,
metabolism, and excretion. Among these, the metabolism
is particularly interesting because the activity of several
drug metabolizing enzymes are significantly influenced by
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variation in the genes coding them.5–7 This opens up for
the use of genotyping of drug metabolizing enzymes to pre-
dict PKs and potentially provide information about decrease
in efficacy or susceptibility to adverse reactions.6,7
Carboxylesterase 1 (CES1) is a hydrolase, and is the
principal enzyme in the metabolism of commonly pre-
scribed drugs, such as MPH,8 clopidogrel,9 and the
angiotensin-converting enzyme inhibitor prodrugs.10,11 This
enzyme has also been implicated in the metabolism of
endogenous compounds, such as esters of cholesterol and
triglycerides.12 Besides serving as potential substrates for
CES1, endogenous molecules with a cholesterol-like struc-
ture have been implicated in the regulation of the activity of
the enzyme by allosteric binding to its superficial ligand
binding site, the so-called Z-site.13–15
Some individuals carry a hybrid of carboxylesterase 1
pseudogene 1 (CES1P1) and a segment of CES1. This
hybrid has been designated CES1A2, whereas CES1 fre-
quently is referred to as CES1A1.16,17 Collectively, CES1A1
and CES1A2 are often referred to as CES1A. CES1A2 is
composed of the promoter and exon 1 of CES1P1 and a
duplicated segment of CES1 containing exons 2–14.
Because the most common promoter in CES1A2, is mark-
edly weaker than that of CES1A1, presence of CES1A2 is
usually not associated with significantly increased amounts
of CES1 mRNA.16 However, there is a promoter haplotype
of CES1A2 with a CES1A1-derived segment containing two
overlapping Sp1 sites that exhibits significantly higher tran-
scriptional activity as compared with CES1A2 haplotypes
without these sites, the high-activity promoter.18 Several
single nucleotide polymorphisms (SNPs) of CES1 have
been reported, including rs71647871, also designated
G143E or p.Gly143Glu as it leads to a change of glycine to
glutamic acid at position 143, a variation that has been
associated with a significantly decreased rate of drug
metabolism.19,20 Another variant, CES1A1c, is a haplotype
defined by a series of SNPs, preferentially located in exon
1, that has been associated with reduction in CES1 mRNA
expression but without marked impact on drug metabolizing
activity.21,22
Because the frequencies of variants of CES1 with a func-
tional impact are low (Ferrero-Milliani, unpublished) it is
likely that variation in this gene explains only a relatively
small proportion of the variation in the PKs of MPH. Hence,
other types of biomarkers may be required for prediction of
the kinetics of drugs metabolized by CES1 on the individual
level.
Using metabolomics approaches, totally new insights
have been gained about the mode of action of a variety of
drugs and the mechanisms implicated in variation in
response to treatment with key classes of therapies, includ-
ing antidepressants,23 statins,24 and antihypertensives.25
Accordingly, metabolomics is a tool, which may prove
helpful in the identification of biomarkers for prediction of
drug response.
Several enzymes implicated in drug metabolism also
have endogenous substrates.26,27 Knowledge about endog-
enous substrates and small molecules of endogenous ori-
gin modulating the activity of such an enzyme may provide
clues to the identification of biomarkers in the blood that
correlate with its activity in the liver.28
The aim of the present study was to identify predose
endogenous metabolites that correlate with the PKs of
MPH and variation in the gene encoding CES1, the princi-
pal enzyme in the metabolism of this drug, besides gaining
new insights into the physiological role of this enzyme.
MATERIALS AND METHODS
Study design, sampling, genetic analyses, and
pharmacokinetic analyses
Data from a previous study in which we investigated the
influence of variation in the gene encoding CES1 on the PK
variables of MPH in 44 healthy volunteers,29 were made
available to the present study. In brief, the 44 volunteers,
consisting of 19 men and 25 women aged 20–29 years and
with a body mass index ranging from 18–28, had been
selected from a total of 200 recruited subjects on the basis
of CES1 genotyping and classified into six CES1 genotype
groups, which included the CES1 wildtype genotype and
five genotypes of CES1 with presumed or documented
effect on drug metabolism. These six groups were desig-
nated 1–6 and consisted of group 1: wild type with 2 copies
of CES1 and without nonsynonymous SNPs, n5 16; group
2: carriers of four CES1 copies including two CES1A2
copies, n55; group 3: carriers of the 143E allele
(rs71647871), n5 6; group 4: carriers of three CES1 copies
including one CES1A2 copy with overlapping Sp1 sites con-
ferring increased transcriptional activity, n5 2; group 5: car-
riers of the CES1A1c variant, n54; and group 6: carriers
of three copies of CES1 including one CES1A2 copy, which
carries the common and low-activity promoter, n5 10. One
of 17 subjects with the wild-type genotype caught a cold
with fever and did not complete the study according to
the protocol. Hence, this group consisted of 16 subjects.
The characteristics of the study subjects in the six geno-
type groups are listed in Table S1. The study had been
designed as a prospective, open labeled, single armed trial
in which the subjects from all genotype groups received a
single dose of 10 mg MPH (Ritalin; Novartis, Basel, Switzer-
land) after a standardized breakfast. Serial blood samples
for analysis of plasma concentrations of MPH (d-MPH and
l-MPH) and its metabolites, which are d-ritalinic and l-ritalinic
acid (d-RA and l-RA), were collected 0.5, 1, 1.5, 2, 2.5, 3,4,
6, 8, 10, 24, and 33 hours after dose administration. Non-
compartmental methods were used to determine area under
the curve (AUC)0-inf, area under the concentration-time curve
from time 0 to infinity; Cmax, the maximum post-dose con-
centration; Tmax, time at which Cmax occurs; and t1=2, termi-
nal elimination half-life of d-MPH, l-MPH, d-RA, and l-RA.
We examined whether these PK variables differed between
CES1 genotypes using an unpaired Wilcoxon Test with cor-
rection by the Benjamini & Hochberg method to control for
false discovery rates based on significance set to q< 0.2.30
The PK variables of the six genotype groups are listed in
Table S2.
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Samples for metabolomics profiling
Blood samples for metabolomics profiling had been col-
lected immediately before the standardized breakfast using
4-mL tubes containing EDTA (Becton Dickinson). After cen-
trifugation of the tubes, plasma was harvested and immedi-
ately frozen by submergence in a mixture of ethanol and
dry ice. The plasma samples were stored at 2808 until
analysis.
Metabolomics profiling: liquid chromatography and
mass spectroscopy targeted metabolomics analyses
Targeted metabolomics analyses, summarized below, were
performed using standard operating procedures based on
previously published methods. More detailed method
descriptions and target lists are given in the Supplemen-
tary Material.
Biogenic amine profiling
Internal standards were added to 5 ll plasma, reduced with
tris(2-carboxyethyl)phosphine, extracted via a protein pre-
cipitation step, and derivatized using AccQ-Tag (Waters
Chromatography, Etten-Leur, The Netherlands), after which
the samples were analyzed using an AccQ-Tag Ultra col-
umn coupled to a Xevo-TQS ultra-performance liquid
chromatography-tandem mass spectrometry system
(Waters Chromatography).31
Positive and negative lipid profiling
We took 10-lL and 20-lL plasma samples that were spiked
with calibration and internal standards and extracted using
isopropyl alcohol (for the positive lipid platforms) or metha-
nol (for the negative lipid platforms). Samples were ana-
lyzed using an ACQUITY UPLC system with an HSS T3
column coupled to a 6530 Accurate Mass QToF (Agilent
Technologies, Santa Clara, CA).32
Bile acid profiling
Bile acid extraction was performed by adding methanol con-
taining internal standards to 50 lL plasma. Samples were
analyzed using an ACQUITY UPLC system with an HSS
T3 column coupled to a 6530 Accurate Mass QToF (Agilent
Technologies).
Following liquid chromatography-mass spectrometry anal-
ysis, data was preprocessed by performing peak inte-
gration, background correction, and determination of the
relative ratios between metabolites and their corresponding
internal standards. The metabolite units were expressed as
the peak area ratios of the target analyte to the respective
internal standard. An in-house written tool was applied
using the QC samples to compensate for shifts in the sen-
sitivity of the mass spectrometer throughout the batches.
Both internal standard correction and QC correction were
applied to the dataset before reporting results. Quality
assurance of metabolite measurements was performed
using the QC relative standard deviation (RSDqc). For
amines, reported compounds had an RSDqc <15%, for
positive and negative lipids RSDqc <20%, and for bile
acids RSDqc <30%.
Processing of metabolomics data and statistical
analysis
Data processing and analysis was performed in the open-
source statistical software, R version 3.2.2.33 Initial testing
determined much of the data was skewed from normal.
Hence, log transformation of the data was used for all sub-
sequent analyses. Significant correlation between outcomes
and metabolites was tested by linear regression.
Correlation coefficients (r) were calculated using the
Pearson’s product-moment correlation test as used in the
cor.test function. Comparisons of genotype variants to wild-
type genotype were tested using an unpaired Wilcoxon
Test. A retrospective power analysis was conducted on the
dataset in Stage et al.29 2017 showing that a minimum of 6
subjects per group, more precisely 5.06 subjects, was
required to detect a difference between groups. Therefore,
genotype comparisons were restricted to only those groups
that had at least >5 subjects, namely groups 1 (wild type)
and groups 3 and 6. Multiple testing correction for each set
of comparisons was performed using the Benjamini &
Hochberg correction method to control for false discovery
rates with significance set to q< 0.1.30 With the significance
set at q< 0.1, the results should include at least 90% true
positives.
In vitro inhibition study
The ester substrate, p-nitrophenyl acetate, the bile acids
sodium glycocholate hydrate, sodium taurochenodeoxycho-
late, sodium taurocholate, lithocholic acid, deoxycholic acid,
sodium glycochenodeoxycholate, chenodeoxycholate, and
cholic acid were purchased from Sigma-Aldrich (St. Louis,
MO). Diltiazem hydrochloride, an inhibitor of CES1, served
as a positive control and was purchased from Napp Phar-
maceuticals Research (Cambridge, UK). Recombinant
human CES1 (CES1b/CES1A1), the major isoform in the
human liver, was from BD Gentest (Woburn, MA), and the
p-nitrophenol was purchased from Fluka (Buchs, Switzer-
land). Other chemicals were of liquid chromatography-mass
spectrometry grade and also commercially available. Glyco-
cholic acid was only available as a hydrate with an unspeci-
fied number of water molecules. For calculation of the
molecular mass of this compound, we assumed presence
of two water molecules in it.
Inhibition of CES1 by the bile acids was investigated by
incubation with the recombinant enzyme in the presence of
p-nitrophenyl acetate. The final concentration of this sub-
strate and the enzyme was 100 mM and 10 mg/mL, respec-
tively. The bile acids were incubated at six concentration
levels ranging from 0.33–1200 mM. Reactions containing
enzyme but without bile acids were also prepared. A reac-
tion mixture with substrate but without enzyme was
included as a negative control. Dimethyl sulfoxide in a final
concentration of 2% v/v was used for dissolution of the bile
acids. This dimethyl sulfoxide concentration was previously
found to have only negligible effect on CES1 activity.11 All
incubations were performed in 96-well pureGrade BRAND
plates (BRAND, Wertheim, Germany) in 100 mM phosphate
buffer at 378C in a final volume of 200 mL. The concentra-
tion of the hydrolytic product of the substrate, that is,
p-nitrophenol, was determined by measurement of its
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absorbance at 405 nm after 3 minutes using a Sunrise
microplate reader (Tecan, Gr€odig, Austria). The absorbance
readings were corrected for spontaneous hydrolysis by sub-
tracting the absorbance of the negative control. The sam-
pling time was found to be within the linear range of the
reaction. All reactions were performed in triplicate. The
half-maximal inhibitory concentration (IC50) constants were
determined using nonlinear regression in Prism, version
6.07 (GraphPad Software, San Diego, CA).
In silico analysis
A docking study was carried out to decipher the preferred
CES1 binding site of the seven bile acids for which we
determined IC50 values in the in vitro analysis, namely, gly-
cocholate, taurochenodeoxycholate, taurocholate, deoxy-
cholic acid, glycochenodeoxycholate, chenodeoxycholic,
and cholic acid. For this purpose, the coordinates of human
CES1 in complex with taurocholate in the catalytic site and
in the Z-site (Protein Data Bank code 2DR0) were obtained
from the Research Collaborator for Structural Bioinformatics
Protein Data Bank. The structure preparation and docking
calculations were performed using CLC Drug Discovery
Workbench (CLC Drug Discovery Workbench version 2.0.
CLC Bio-Qiagen, Aarhus, Denmark). Water molecules and
cofactors were removed from the complex and the mono-
meric form of the protein was protonated at pH 7.2. The
binding sites were defined with a 15 A˚ radius around tauro-
cholate, both in the catalytic site and the Z-site. To assess
whether the docking program was able to reproduce crys-
tallographic binding modes, taurocholate was docked back
in the two binding sites. Subsequently, the seven bile acids
were docked into the defined binding sites assuming the
protein to be completely rigid in all docking studies to
reduce computational costs. A total of 100 conformations
were computed for each compound and the first ranked
conformation of each of the compounds, that is, the confor-
mations with the lowest docking scores and the most stable
interactions inside a cavity, were considered for further
analysis. Analysis of binding was performed using the soft-
ware Molecular Operating Environment, 2015.10 (Chemical
Computing Group, Montreal, QC, Canada).
RESULTS
Lipid metabolites were measured either in positive or nega-
tive mode. In positive mode, 153 lipid metabolites were
measured (Supplementary Material). They belonged to
the following lipid classes: ceramide (Cer), cholesterol
esters (CEs), diacylglycerol (DG), lysophosphatidylcholine
(LPC), phosphatidylcholine (PC), phosphatidylethanolamine
(PE), sphingomyelin (SM), and triglycerides (TG). In the
negative mode, 61 lipids were measured belonging to: fatty
acids (FAs), LPC, lysophosphatidylethanolamine (LPE),
SN1, and SN2 classes. A measure of 13 individual bile
acids (primary and secondary) and a panel of 32 amines
were also measured.
Predose metabolomics data were correlated with the PK
profile of MPH and its metabolite RA (Table 1). Because
the study subjects were of similar age (20–29 years) and
body mass index (18–28 kg/m2) evaluation of these covari-
ates indicated that they did not possess enough variance to
justify adding them to the model (data not shown).
When testing all positive lipids as a set, baseline meas-
urements of two lipids showed significance with measured
outcomes (Table 1). PC(38:5) was negatively correlated
with both AUC of d-MPH and the Cmax of d-MPH, and
Cer(d18:1/24:1) was positively correlated with the half-life
of the metabolite l-RA.
Separating positive lipids by class before testing results
revealed three additional suggestive findings, namely a
negative correlation between CE(20:5) and AUC of d-MPH,
and positive correlations between DG(36:3) and AUC of d-
RA and PC(36:3) and AUC of l-RA.
Testing all negative lipids as a set did not reveal any sig-
nificant correlations between baseline measurement and
outcome (Table 1). Again, separating the negative lipids by
class identified two additional lipids having suggestive cor-
relations between baseline measurements and various out-
comes. Specifically, SNI-LPC(22:5-w6) was positively
correlated with the AUCs of d-RA and l-RA. SN2-LPC(20:5)
was negatively correlated with Cmax of d-MPH.
Although no significance was found after correction for
multiple testing of the correlations between the PK out-
comes and the baseline measurements of triglycerides with
highly unsaturated fatty acids, low P values were observed
for the half-life, Tmax, and AUC of d-MPH (P< 0.10;
q<1.00). These results may be suggestive of a need for
future study.
No significant correlations were found with triglycerides
having lower numbers of double bonds in the fatty acids, or
using a measurement of TG/PC ratio.
When testing predose measurements of bile acids indi-
vidually for correlation with outcomes (Table 1), although
some P values were low, there was no significance after
multiple-testing correction. However, when categorized
based on primary, secondary, and conjugated status, as
detailed in Supplementary Material, there were significant
correlations with half-life of l-RA in both primary and
primary-conjugated bile acids. Other categorized measures
were not significant, nor were there any correlations with
other bile acid categories.
Testing predose measurements of the 32 amines for cor-
relation with outcomes showed no significant results.
On testing correlations between CES1 genotype and PK,
significance was mostly seen in the comparison between
the normal genotype (group 1) and the group with the
rs71647871 143E allele (n5 6) with a higher AUC of
d-MPH, half-life of d-MPH, and Cmax of d-MPH in the latter
of these two groups (Table 2). Detailed analysis of the
genotype/PK comparisons shown in Table 2 have been pre-
viously reported using a slightly different statistical approach,
which involved application of the Kruskal-Wallis test.29
Due to the large impact of the 143E allele of rs71647871
on MPH metabolism, testing of correlation between geno-
type groups and levels of predose metabolites was restricted
to comparison of carriers of 143E allele with the control
group (Table 2, Figure S1). For positive lipids, the only sig-
nificant comparison found with genotype was for PC(38:5),
which was present at a higher concentration at baseline in
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group 1 (median log value: 1.23) than group 3 (median log
value: 0.96; Table 3, Figure S2). Group 3 had decreased
concentrations of metabolites with high polyunsaturated fatty
acid lipids (PUFAs), specifically TG(56:6) and TG(56:5),
when compared to group 1. There were no other significant
correlations.
The IC50 values differed significantly between the bile
acids (Figure 1). We found that chenodeoxycholic acid and
taurocholic acid inhibited with IC50 of 13.55 and 19.51 lM,
respectively, which is in a range similar to diltiazem, a
known inhibitor of CES1.
Taurochenodeoxycholic acid had an IC50 value, which
was more than fourfold higher; whereas glycochenodeox-
ycholic acid had an IC50 10-fold higher than diltiazem.
We were not able to determine the IC50 value of litho-
cholic acid because it could not be dissolved in aqueous
buffer.
Docking analysis predicted a preference of all bile acids
for the catalytic site over that of the Z-site of the enzyme,
except for deoxycholic acid (Table 4). Taurocholic acid,
taurochenodeoxycholic acid, and glycochenodeoxycholic
acid were predicted to bind to the active site with the high-
est affinity. Chenodeoxycholate, taurocholate, and tauroche-
nodeoxycholic acid, the strongest inhibitors of CES1 in our
in vitro analysis, were found to interact more strongly with
the Z-site of the enzyme than the four other bile acids in
our docking analysis (Table 4). There was a weak correla-
tion between docking scores of the bile acids for the cata-
lytic pocket of CES1 and the IC50 values (r5 0.44). The
correlation between the docking scores of the bile acids for
the Z-site and the IC50 values was strong (r5 0.86). The
docking analysis also revealed that taurocholate and other
compounds with a sulfate group are stabilized by an ionic
interaction with Lys92 at the entrance of the active site,
Table 1 Significant correlations between lipids or bile acids and outcomes by testing full lipid panels and after classification of lipids
Lipid Outcome Correlation (r) P value Q valuea
Positive lipids – all
PC(38:5) AUC d-Ratio 20.61912 0.000012 0.018930
PC(38:5) AUC d-MPH 20.60946 0.000018 0.028101
Cer(d18:1/24:1) Half-life l-RA 0.59135 0.000037 0.057003
PC(38:5) Cmax d-MPH 20.56358 0.000102 0.155770
Positive lipids - by class
Cer(d18:1/24:1) Half-life l-RA 0.59135 0.000037 0.001490
PC(38:5) AUC d-Ratio 20.61912 0.000012 0.004825
PC(38:5) AUC d-MPH 20.60946 0.000018 0.007163
PC(38:5) Cmax d-MPH 20.56358 0.000102 0.039706
CE(20:5) AUC d-MPH 20.45900 0.002232 0.089283
PC(36:3) AUC l-RA 0.53377 0.000272 0.106196
DG(36:3) AUC d-RA 0.40624 0.007597 0.151942
Negative lipids - by class
SN2-LPC(20:5) Cmax d-MPH 20.53120 0.000421 0.050481
SN1-LPC(22:5-w6) AUC d-RA 0.52534 0.000500 0.094993
High PUFA triglycerides
Half-life d-MPH 20.30436 0.050028 0.400225
Tmax d-MPH 20.28994 0.062524 0.500195
AUC d-MPH 20.25876 0.097997 0.783973
Bile acids
Primary bile acids Half-life l-RA 0.369441 0.024425 0.195402
Primary conjugated bile acids Half-life l-RA 0.428832 0.008090 0.064723
AUC, area under the curve; Cmax, peak plasma concentration; MPH, methylphenidate; RA, ritalinic acid; PUFA, polyunsaturated fatty acid lipid; Tmax, time of
maximum plasma concentration.
The figures in italics represent p-value < 0.1 and q-value > 0.1.
aQ values for the positive and negative lipids are by classs and are for guidance for future research rather than indicating significance.
Table 2 Significant results from testing between genotypes for outcomes of
pharmacokinetics
Outcome Direction P value Q value
Group 1 vs. group 3 (143E allele)
AUC d-MPH Group 3 higher 0.000454 0.003630
Half-life d-MPH Group 3 higher 0.000982 0.007860
Cmax d-MPH Group 3 higher 0.007112 0.056892
AUC, area under the curve; Cmax, peak plasma concentration; MPH,
methylphenidate.
Table 3 Significant results from testing between genotypes for outcomes of
lipids
Lipid Direction P value Q value
Group 1 vs group 3 positive lipids
PC(38:5) Group 1 higher 0.007988 0.039939
Group 1 vs. group 3 high PUFA triglycerides
TG(56:6) Group 1 higher 0.006085 0.091271
TG(56:5) Group 1 higher 0.007988 0.119818
PUFA, polyunsaturated fatty acid lipid.
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thus potentially compromising access of substrate to this
site (Figure 2).
The carboxyl group containing bile acids, such as cheno-
deoxycholate, are located with their carboxyl group close to
the catalytic triad amino acid Ser221, which could hinder
nucleophilic substrate attack by this amino acid. The bind-
ing of taurocholate and chenodeoxycholate to the Z-site
seem to be stabilized by Gly356 and Lys414 (Figure 3).
DISCUSSION
This study is the first to correlate small endogenous mole-
cules in the blood with hepatic activity of CES1 as deter-
mined by the PKs of a drug, MPH. Its main findings were
the identification of lipids that not only correlated with the
PK of MPH and RA but also with CES1 genotype and sug-
gested a role of CES1 in lipid metabolism. Involvement of
specific bile acids in the regulation of the activity of CES1
was supported by the finding of an ability of two bile acids
to inhibit CES1 in vitro, which was supplemented with in
silico observations to determine the mechanism underlying
the inhibition.
The metabolites that correlated with PK variables of d-
MPH included lipid metabolites containing eicosapentaenoic
acid (EPA) 20:5 and docosapentaenoic acid (DPA) 22:5,
FAs commonly found in fish oil. The EPA and DPA in FA,
LPC, CE, and PC containing metabolites were found to be
correlated with the Cmax and AUC of d-MPH. Both EPA and
DPA are long-chain PUFAs that are important in production
of eicosanoids, signaling molecules, which regulate inflam-
mation and metabolism.34
Lipids containing EPA were negatively correlated with d-
MPH concentration, thus decreased EPA would be associ-
ated with increased MPH level and, hence decreased
CES1 activity. This supports the hypothesis that CES1
activity determines the quantity of PUFAs in triglycerides
and regulates release of lipoproteins.35 Lower CES1 activity
would result in decreased PUFAs in hepatic lipids and the
release of those lipids modulating the composition and
release of lipoproteins from the liver.35,36 The significant
lipid metabolites with 20:5 as the FA moiety identified in
this study indicate that CES1 preferentially regulates the
quantity of EPA in lipids. Alternatively, higher levels of
omega 6 PUFA, such as DPA, which, in our study, had a
positive correlation with RA AUC, may inhibit CES1 activ-
ity14 providing a feedback regulation to control lipoprotein
production. This is in line with previous in vitro findings that
fatty acids inhibit CES1, particularly unsaturated fatty
acids.14
The finding of lower levels of PUFA in PC and TG in the
genotype group with the 143E allele, which was associated
with significantly decreased CES1 activity, should be inter-
preted with caution due to the small sample size. However,
Figure 1 Dose response curves for compounds inhibiting carboxylesterase 1 (CES1) activity. Half-maximal inhibitory concentrations
(IC50) are shown in brackets.
Table 4 Docking scores of bile acids for the active site and Z-site of
carboxylesterase 1
Compound
Docking score
active site
Docking
score Z-site
Chenodeoxycholic acid 253.00 251.50
Taurocholic acid 267.10 254.41
Taurochenodeoxycholic acid 263.20 251.00
Glycochenodeoxycholic acid 268.00 248.80
Deoxycholic acid 241.50 247.20
Cholic acid 252.00 246.70
Glycocholic acid 253.20 243.60
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it connects CES1 activity with physiological functions and
allows for improved prediction of this enzyme activity
based on the combination of genetics and metabolomics
information.
We found that levels of bile acids marginally correlated
with l-RA and d-MPH PK. Bile acids possess a variety of
physiological functions37 and have been linked with
response to drugs, such as simvastatin.24 Moreover,
cholesterol-like molecules, including the bile acids cholate
and taurocholate, have been shown to bind to CES1, which
is thought to shift the trimer-hexamer equilibrium of the
enzyme toward the trimer, the catalytically active form.13
Hence, we hypothesize that the correlations of bile acids
with l-RA and d-MPH PK in the present study reflect
involvement of bile acids in the regulation of CES1 activity.
However, we cannot exclude that these correlations have
Figure 2 Docking of taurocholate into the catalytic site (a) and
the Z-site (b). The binding of taurocholate in the catalytic pocket
of carboxylesterase 1 is stabilized by an ionic interaction with
Lys92 at the entrance of this site. Binding of taurocholate to the
Z-site appears to be stabilized by Lys414. Figure 3 Docking of chenodeoxycholate into the catalytic site (a)
and the Z-site (b). Chenodeoxycholate is located deep in the cat-
alytic pocket Ser221 close to the catalytic triad amino acid
Ser221. The binding of chenodeoxycholate to the Z-site appears
to be stabilized by Lys414.
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occurred as a result of a bias due to the small sample size
of our cohort.
Additionally, the correlations may have resulted from indi-
rect regulation of lipid metabolism by farnesoid X receptor.
Using in vitro analysis, we revealed large differences
between bile acids in the ability to inhibit CES1. Two bile
acids had IC50 values in a range sufficiently low to inhibit
CES in vivo,38 thus arguing in favor of a role of bile acids in
the regulation of CES1 activity.
Our in vitro analysis of the bile acids were supplemented
with an in silico study of these molecules to provide insights
into their molecular interactions with CES1 and resultant
effect on the enzyme. It suggested that bile acids are capa-
ble of binding to the catalytic pocket as well as the Z-site of
CES1 but have larger affinity to the former of these
two sites. Using X-ray crystallography, a previous study
observed binding of taurocholate to both the Z-site and the
active site of CES1, which is consistent with our findings.
Inhibitors that both bind to the active site and the Z-site of
CES1 are most likely mixed-type inhibitors, which may
include bile acids.9 The docking scores of the ligands in the
catalytic pockets and the Z-site may not necessarily be
comparable with respect to impact on enzyme activity. The
strong correlation between the docking scores for the Z-site
and the IC50 values suggests that the docking values for
this site directly translates into enzyme activity.
Several factors determine the level of FA and bile acids,
including diet and body weight. Hence, it is possible that
these and similar factors have an impact on the activity of
CES1 and the metabolism of several of drugs.39
The lack of correlation between the level of amines and
PK of MPH is noteworthy as amines have not been associ-
ated with CES1. This is opposed to lipids that correlated
with the PK of MPH in the present study and previously
have been identified as substrates and allosteric regulators
of CES1.13 Hence, our findings are in accordance with the
existing knowledge about substrates and endogenous regu-
lators of CES1 activity.
In summary, the findings of the present study that lipid
and bile acid metabolites were correlated with apparent
activity and genotype of CES1 are suggestive of a role of
CES1 in lipid metabolism and a physiological role of the
enzyme. Our findings also open up for prediction of the PK
of drugs metabolized by CES1 on the individual level and
for improved therapy with these drugs.
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